Every minute counts when a newborn is critically ill. Traditional diagnostic methods often fall short in identifying rare genetic disorders early, leading to delayed treatments and prolonged uncertainty for families. Whole Genome Sequencing (WGS)—and especially ultrarapid WGS (urWGS)—is changing that.

WGS offers a comprehensive view of an infant's genetic makeup, enabling faster and more accurate diagnoses. With turnaround times as short as 5–8 days, urWGS can detect rare monogenic disorders in days rather than weeks or months, helping clinicians intervene sooner and improve outcomes.

A compelling case study featured in the article shows how Revvity Omics used urWGS and biochemical screening to help diagnose a life-threatening condition in a newborn within 53 hours—proving the power of early detection.

Revvity Omics’ urWGS service includes:

• Mitochondrial genome sequencing
• Biochemical testing
• cCMV analysis
• SNV and CNV detection
• Flexible sample types, including dried blood spots

With fast, accurate results and actionable insights, Revvity Omics is helping clinicians end the diagnostic odyssey—and give every newborn a healthier start.

Download the full article to learn more about how urWGS is shaping the future of neonatal care.

This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.